Sirolimus by OrphAI Therapeutics for Pulmonary Arterial Hypertension: Likelihood of Approval
Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase II drugs for Pulmonary Arterial Hypertension have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how Sirolimus's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Sirolimus overviewSirolimus is under development for the treatment of bronchiolitis obliterans post lung transplant and pulmonary sarcoidosis. The drug candidate is administered through inhalational route. It targets mammalian target of rapamycin (mTOR). It is being developed artificial intelligence based Guardian Angel Platform. The drug candidate was also under development for the treatment of lymphangioleiomyomatosis (LAM), tuberous sclerosis complex and pulmonary arterial hypertension.OrphAI Therapeutics overviewOrphAI Therapeutics (OrphAI), formerly AI Therapeutics Inc, is a biopharmaceutical company that identifies and develops treatments for neurological diseases and cancers. It investigates LAM-001 program against pulmonary sarcoidosis and bronchiolitis obliterans disease caused after lung transplantation resulting in obstruction of the smallest airways of the lungs. The company is also evaluating AIT–101 drugs to treat amyotrophic lateral sclerosis and AIT-102 for rare diseases. OrphAI is headquartered in Guilford, Connecticut, the US. For a complete picture of Sirolimus's drug-specific PTSR and LoA scores, buy the report here.
Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.
What's Your Reaction?
